Cover Image
市場調查報告書

全球骨髓發育不良症候群市場:2015年∼2019年

Global Myelodysplastic Syndrome Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 350494
出版日期 內容資訊 英文 81 Pages
訂單完成後即時交付
價格
Back to Top
全球骨髓發育不良症候群市場:2015年∼2019年 Global Myelodysplastic Syndrome Market 2015-2019
出版日期: 2016年01月20日 內容資訊: 英文 81 Pages
簡介

所謂骨髓發育不良症候群是血液疾病的一種,由骨髓發病並擴大到血液中。特徵是骨髓所製作的造血細胞無法充分成長,所以常見於60歲以上的長者。全球骨髓發育不良症候群市場預測在2015年∼2019年這段期間,年複合成長率將為9.93%。

本報告提供全球骨髓發育不良症候群市場相關調查分析,為您彙整產業概要,地區市場概要,推動市場的要素,市場課題,市場趨勢,主要供應商等資訊。

第1章 摘要整理

第2章 報告的範圍

第3章 產品簡介

第4章 市場調查的方法

  • 調查方法
  • 經濟指標

第5章 簡介

第6章 疾病概要

  • 疾病的理解
  • 風險因素
  • 徵兆與症狀
  • 病理學
  • 種類
  • 診斷
  • 流行病學
  • 治療

第7章 開發平台·組合

第8章 市場的狀況

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第9章 市場區隔:藥物級

  • 烷化劑
  • 細胞毒性抗生素
  • 異構轉化梅抑制劑
  • 其他

第10章 市場區隔:給藥途徑

  • 口服
  • 非口服

第11章 各地區市場區隔

  • 歐洲/中東/非洲
  • 亞太地區

第12章 推動市場的要素

  • 高齡人口的增加
  • 未滿足需求
  • 診斷工具的利用

第13章 促進要素的影響

第14章 市場課題

第15章 促進要素與課題的影響

第16章 市場趨勢

第17章 供應商狀況

第18章 主要供應商分析

第19章 附錄

第20章 Technavio的其他報告

另紙一覽

目錄
Product Code: IRTNTR7587

About Myelodysplastic Syndrome

Myelodysplastic syndrome is a group of hematologic disorders that arise in the bone marrow and spread into the blood. The syndrome is characterized by the inability of the hematopoietic cells produced in the bone marrow to attain maturity. Cytological dysplasia is a common feature of the syndrome, progressing to acute myeloid leukemia in about 30% of individuals with myelodysplastic syndrome. The disease is age-related, mostly affecting people aged 60 and above. Smoking, exposure to radiation, contact with chemicals such as benzene, genetic mutations, and chemotherapy can cause myelodysplastic syndrome.

Technavio's analysts forecast the global myelodysplastic syndrome market to grow at a CAGR of 9.93% during the period 2015-2019.

Covered in this report

The report covers the present scenario and the growth prospects of the global myelodysplastic syndrome market for 2015-2019. To calculate the market size, we consider revenue generated from the sales of various drugs used for treating myelodysplastic syndrome.

The report describes the market by region:

  • Americas: The US, Canada, Mexico, and Brazil
  • EMEA: The UK, Germany, Italy, France, Spain, Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE
  • APAC: Japan, China, Australia, Singapore, South Korea, and India

Technavio's report, Global Myelodysplastic Syndrome Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Celgene
  • Novartis
  • Otsuka

Other Prominent Vendors

  • Acceleron Pharma
  • Amgen
  • Astellas
  • Astex
  • Actinium Pharmaceuticals
  • Bellicum Pharmaceuticals
  • BioLineRx
  • Celator Pharmaceuticals
  • Cornerstone Pharmaceuticals
  • CTI BioPharma
  • Eli Lilly
  • Gamida Cell
  • GlaxoSmithKline
  • KaloBios Pharmaceuticals
  • Kiadis Pharma
  • Mirati Therapeutics
  • Onconova Therapeutics
  • Strategia Therapeutics
  • Sumitomo Dainippon Pharma
  • Sunesis Pharmaceuticals
  • Targazyme
  • TetraLogic Pharmaceuticals

Market driver

  • Rise in aging population
  • For a full, detailed list, view our report

Market challenge

  • Use of off-label drugs
  • For a full, detailed list, view our report

Market trend

  • Rise in public awareness
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Product profile

  • REVLIMID
  • VIDAZA
  • Dacogen
  • Glivec/Gleevec

PART 04: Market research methodology

  • Research methodology
  • Economic indicators

PART 05: Introduction

  • Key market highlights

PART 06: Disease overview

  • Understanding the disease
  • Risk factors
  • Signs and symptoms
  • Pathophysiology
  • Types
  • Diagnosis
  • Epidemiology
  • Treatment

PART 07: Pipeline portfolio

  • Information on pipeline candidates

PART 08: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 09: Market segmentation by drug class

  • Alkylating agents
  • Cytotoxic antibiotics
  • Topoisomerase inhibitors
  • Others

PART 10: Market segmentation by route of administration

  • Oral
  • Parenteral

PART 11: Geographical Segmentation

  • Myelodysplastic syndrome market in EMEA
  • Myelodysplastic syndrome market in APAC

PART 12: Market drivers

  • Rise in aging population
  • Unmet medical needs
  • Use of diagnostic tools

PART 13: Impact of drivers

PART 14: Market challenges

  • Use of off-label drugs
  • Adverse effects of drugs
  • High cost of drugs

PART 15: Impact of drivers and challenges

PART 16: Market trends

  • Rise in public awareness
  • Patient assistance programs
  • Increase in R&D
  • Intense competition

PART 17: Vendor landscape

  • Competitive scenario
  • Market share analysis 2014
  • Other prominent vendors

PART 18: Key vendor analysis

  • Celgene
  • Novartis
  • Otsuka Holdings

PART 19: Appendix

  • List of abbreviations

PART 20: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Myelodysplastic syndrome: Risk factors
  • Exhibit 03: Myelodysplastic syndrome: Signs and symptoms
  • Exhibit 04: History of myelodysplastic syndrome classification system
  • Exhibit 05: FAB classification system: Types of myelodysplastic syndrome
  • Exhibit 06: WHO classification system: Types of myelodysplastic syndrome
  • Exhibit 07: IPSS classification: Factors and score
  • Exhibit 08: IPSS-R classification: Cytogenetic score
  • Exhibit 09: IPSS-R classification: Score values
  • Exhibit 10: IPSS-R classification: Risk categories and scores
  • Exhibit 11: Diagnostic tests for myelodysplastic syndrome
  • Exhibit 12: Myelodysplastic syndrome: Global incidence based on age 2007-2011 (years)
  • Exhibit 13: Myelodysplastic syndrome: Incidence in US by race 2007-2011
  • Exhibit 14: Treatment options for myelodysplastic syndrome
  • Exhibit 15: Chemotherapeutic agents
  • Exhibit 16: Immunotherapy drugs
  • Exhibit 17: Supportive therapy for myelodysplastic syndrome
  • Exhibit 18: Drugs that received orphan designation for treatment of myelodysplastic syndrome
  • Exhibit 19: Myelodysplastic syndrome: Drug pipeline
  • Exhibit 20: Global myelodysplastic syndrome market ($ millions)
  • Exhibit 21: Five forces analysis
  • Exhibit 22: Global myelodysplastic syndrome market segmentation by drug class
  • Exhibit 23: Global myelodysplastic syndrome market segmentation by route of administration
  • Exhibit 24: Global myelodysplastic syndrome market segmentation by geography 2014
  • Exhibit 25: Myelodysplastic syndrome market in Americas 2014-2019 ($ millions)
  • Exhibit 26: Myelodysplastic syndrome market in EMEA 2014-2019 ($ millions)
  • Exhibit 27: Myelodysplastic syndrome market in APAC 2014-2019 ($ millions)
  • Exhibit 28: Global myelodysplastic syndrome market segmentation by geography 2014-2019 ($ millions)
  • Exhibit 29: Impact of drivers
  • Exhibit 30: Impact of drivers and challenges
  • Exhibit 31: Ranking of leading companies
  • Exhibit 32: Celgene: YoY growth and revenue of VIDAZA 2012-2014 ($ millions)
  • Exhibit 33: Celgene: YoY growth and revenue of REVLIMID 2012-2014 ($ billions)
  • Exhibit 34: Celgene: Key takeaways
  • Exhibit 35: Otsuka Holdings: Key takeaways
  • Exhibit 36: Novartis: Key takeaways
  • Exhibit 37: Celgene: Product segmentation by revenue 2014
  • Exhibit 38: Celgene: Product segmentation by revenue 2013 and 2014
  • Exhibit 39: Celgene: Geographical segmentation by revenue 2014
  • Exhibit 40: Novartis: Business segmentation by revenue 2014
  • Exhibit 41: Novartis: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 42: Novartis: Geographical segmentation by revenue 2014
  • Exhibit 43: Otsuka Holdings: Business segmentation by revenue 2014
  • Exhibit 44: Otsuka Holdings: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 45: Otsuka Holdings: Geographical segmentation by revenue 2014
Back to Top